Barbara Handelin, PhD 

CEO and President of The 90-10 Institute

As the founder of The 90-10 Institute Dr. Handelin continues her commitment to transformation of the biotech industry toward maximizing health for the public writ large. She is a 40 year veteran entrepreneur and molecular medical geneticist who has been a pioneer in the responsible application of genetics to clinical medicine. Over the last decade, she has turned from technology innovation to redesigning the business and financing of her beloved industry, culminating in the establishment of The 90-10 Institute. 

Dr. Handelin has served on the Board of Directors at RedPath Integrated Pathology,Inc., NeuroPointDx/Stemina She is currently serving on Board of Transformative Bio, LLC. She has also served on scientific advisory boards of several genomics companies (e.g. EXACT Sciences).

Agent for Social Change:  Dr Handelin served on a variety of federal committees and advisory panels on ethics in genetic testing, including the Secretary’s Advisory Panel on Genetics, Health and Society.  For the interest of  Human Subjects Protections, she served for 10 years at Public Responsibility in Medicine and Research (PRIM&R).  As cofounder of BioPontis Alliance, LLC and BioPontis Alliance for Rare Diseases, a 501c(3), she has pushed innovation for translating more good science into good medicine. 

Dr. Handelin took her Ph.D. in Medical Genetics at the Oregon Health Sciences University (thesis work completed at the Massachusetts Institute of Technology).  Dr. Handelin holds a Non-Profit Management Certificate from the University of Delaware.